RBC Capital on Acadia Pharmaceuticals (ACAD): 'Setup Skews Net Favorably'
March 24, 2026 5:54 AM
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $30.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
